A Phase 3, Multicenter, Randomized, Open-Label Study of Avelumab (MSB0010718C) Alone or in Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone in Patients With Platinum-Resistant/Refractory Ovarian Cancer
A Phase 3, Multicenter, Randomized, Open-Label Study of Avelumab (MSB0010718C) Alone or in Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone in Patients With Platinum-Resistant/Refractory Ovarian Cancer
Category & Conditions: Cancer
Medicine: Bavencio (avelumab)
ClinicalTrials.gov Identifier (NCT): NCT02580058
Protocol ID: B9991009
PrintDownloadOpen Plain Language Summary Result: Click here